Skip to content

Study · Animal study (in vivo) · mouse · 2015

4 results

Evidence that Melanocortin Receptor Agonist Melanotan-II Synergistically Augments the Ability of Naltrexone to Blunt Binge-Like Ethanol Intake in Male C57BL/6J Mice.

Navarro M, Carvajal F, Lerma-Cabrera JM, Cubero I, Picker MJ, Thiele TE

Alcoholism, clinical and experimental research24 Jun 2015Cited by 19 (Europe PMC)

PMID26108334 (opens in a new tab)PMCIDPMC4515169 (opens in a new tab)DOI10.1111/acer.12774 (opens in a new tab)PepBankPUB-26108334
Source linkPubMedAsk about this study
Jump to 4 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study4

4 results from studies that gave the peptide. No result from this study comes from people.

  1. 01AnimalAnimal study (in vivo)Efficacy outcome

    In male C57BL/6J mice, MTII blunted binge-like ethanol drinking.

    In plain wordsIn male mice, MTII reduced binge-like alcohol drinking.

    Peptide
    Melanotan II
    Outcome
    DecreaseBinge-like ethanol drinking
    Study

    mousen: not reported in source

    male C57BL/6J mice, binge-like ethanol drinking model
    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both NAL and MTII blunt binge-like EtOH drinking and associated blood EtOH levels, and when administered together, a low dose of MTII (0.26 mg/kg) produces a 7.6-fold increase in the effectiveness of NAL in reducing binge-like EtOH drinking.
    1 context sentence
    Summary · context
    In the present report, a mouse model of binge EtOH drinking was employed to determine whether the MCR agonist, melanotan-II (MTII), would improve the effectiveness of NAL in reducing excessive binge-like EtOH drinking when these drugs were co-administered prior to EtOH access.
  2. 02AnimalAnimal study (in vivo)Efficacy outcome

    In male C57BL/6J mice, MTII blunted blood ethanol levels associated with binge-like drinking.

    In plain wordsIn male mice, MTII lowered the blood alcohol levels linked to binge-like drinking.

    Peptide
    Melanotan II
    Outcome
    DecreaseBlood ethanol levels
    Study

    mousen: not reported in source

    male C57BL/6J mice, binge-like ethanol drinking model
    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Both NAL and MTII blunt binge-like EtOH drinking and associated blood EtOH levels, and when administered together, a low dose of MTII (0.26 mg/kg) produces a 7.6-fold increase in the effectiveness of NAL in reducing binge-like EtOH drinking.
    1 context sentence
    Summary · context
    In the present report, a mouse model of binge EtOH drinking was employed to determine whether the MCR agonist, melanotan-II (MTII), would improve the effectiveness of NAL in reducing excessive binge-like EtOH drinking when these drugs were co-administered prior to EtOH access.
  3. 03AnimalAnimal study (in vivo)Efficacy outcome

    In male mice, low-dose MTII (0.26 mg/kg) with naltrexone produced a 7.6-fold increase in the effectiveness of naltrexone in reducing binge-like ethanol drinking.

    In plain wordsIn male mice, a low dose of MTII made naltrexone work 7.6 times better at reducing binge-like alcohol drinking.

    Peptide
    Melanotan II
    Outcome
    DecreaseNaltrexone effectiveness with MTII co-administration
    Study

    mousen: not reported in source

    male C57BL/6J mice, binge-like ethanol drinking model
    Comparator
    Naltrexone alone
    Outcome group
    Addiction, withdrawal and alcohol intake · Mental health and mood
    Studied dose
    0.26 mg/kgAs given in this study (mouse).

    Measurements

    Increase in naltrexone effectiveness
    7.6 fold
    MTII 0.26 mg/kg with naltrexone

    Source sentences

    Summary
    Both NAL and MTII blunt binge-like EtOH drinking and associated blood EtOH levels, and when administered together, a low dose of MTII (0.26 mg/kg) produces a 7.6-fold increase in the effectiveness of NAL in reducing binge-like EtOH drinking.
    1 context sentence
    Summary · context
    In the present report, a mouse model of binge EtOH drinking was employed to determine whether the MCR agonist, melanotan-II (MTII), would improve the effectiveness of NAL in reducing excessive binge-like EtOH drinking when these drugs were co-administered prior to EtOH access.
  4. 04AnimalAnimal study (in vivo)Mechanism

    In male mice, isobolographic analysis showed that MTII increased the effectiveness of naltrexone in a synergistic manner.

    In plain wordsIn male mice, MTII and naltrexone together worked better than expected from adding their separate effects.

    Peptide
    Melanotan II
    Outcome
    Not applicableInteraction of MTII with naltrexone (isobolographic analysis)
    Study

    mousen: not reported in source

    male C57BL/6J mice, binge-like ethanol drinking model
    Outcome group
    Receptor activity and mechanism · Mental health and mood
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Using isobolographic analysis, it is demonstrated that MTII increases the effectiveness of NAL in a synergistic manner.
    1 context sentence
    Summary · context
    In the present report, a mouse model of binge EtOH drinking was employed to determine whether the MCR agonist, melanotan-II (MTII), would improve the effectiveness of NAL in reducing excessive binge-like EtOH drinking when these drugs were co-administered prior to EtOH access.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    9 Oct 2026, 18:17 UTC

    Study results updated

  2. Version 1

    9 Oct 2026, 03:04 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.